Vildagliptin
Brand: Galvus (EU/IN) / Vilda (BD)
Antidiabetic
DPP-4 inhibitor
Pharmacokinetics
| Half-life | 3 hours |
| Tmax | 1.5 h |
| Bioavailability | 85 % (approx) |
| Protein Binding | 10 % |
| Volume of Distribution | 1 L/kg (approx) |
| Clearance Route | mixed |
| Active Metabolites | no |
| Notes | Usual dose 50 mg bid or 50 mg od with SU; monitor LFTs periodically. |
⚠️ Safety & Warnings
Severity: Mild
Adverse Effects:
Nasopharyngitis, headache, rare hepatic enzyme rise
Contraindications:
Severe hepatic impairment
Precautions:
Check LFTs at baseline and periodically; adjust if combined with SU to reduce hypoglycemia